OAB-049: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)–related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)

Popat, Rakesh; Kazantzi, Aikaterini; Kleinman, David L.; Lichenstein, Carolyn; Paka, Prani; Salter, J. W.; Byrne, Julie; Doherty, Allison; Esposti, Simona Degli

doi:10.1016/s2152-2650(22)00322-6

Clinical Lymphoma Myeloma and Leukemia

2022

DOI: 10.1016/s2152-2650(22)00322-6

|View full text |Cite

OAB-049: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)–related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)

Rakesh Popat¹,

Aikaterini Kazantzi²,

David L. Kleinman³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a pooled analysis of the DREAMM-2 trial among patients who had received at least three prior LoT (median ages 65-67 at baseline), 60% of patients were found to have cataracts on ophthalmologic exams before their first dose of belantamab. 9 This high prevalence is related to several factors, including advancing age itself as a risk factor for cataract development. 10 Our research focused more specifically on patient-reported cataracts, almost half of which were rated as uncomfortable or disruptive when they were diagnosed.…”

mentioning

confidence: 99%

Association between dexamethasone exposure and visually significant cataracts in multiple myeloma

Banerjee,

Hurtado Martínez,

Flores Pérez

et al. 2023

American J Hematol

View full text Add to dashboard Cite

Newer regimens have continued to improve outcomes in multiple myeloma (MM). For many such regimens, dexamethasone (often 20-40 milligrams weekly) is continued alongside other anti-MM agents until progression. A link between systemic dexamethasone and ocular cataracts was first established decades ago, likely due to corticosteroid-related metabolic or oxidative changes within the lens. [1][2][3][4] Despite the ubiquity of dexamethasone in MM regimens, however, relatively few studies have investigated its association with ocular toxicities in MM. In one claims analysis, the prevalence of ocular comorbidities in MM rose with each subsequent line of therapy (LoT) as compared to newly diagnosed MM. 5 Potential mechanisms for this finding include continued dexamethasone, advancing age, and perhaps chronic paraprotein-mediated damage to the lens. 6,7 As a first step toward characterizing the specific impact of dexamethasone on ocular comorbidities, we used patient-reported and Electronic Medical Record (EMR)-derived data to analyze relationships between dexamethasone exposure, patient-reported cataract incidence, and patient-reported cataract severity.We analyzed patient-reported data from users of the HealthTree Cure Hub for MM, an online platform promoted to patients with MM residing in the United States (US) through emails, social media, and community events. As of December 2022, 11 356 patients with MM have created a Cure Hub account. In addition to educational materials

show abstract

mentioning

confidence: 99%

Association between dexamethasone exposure and visually significant cataracts in multiple myeloma

Banerjee,

Hurtado Martínez,

Flores Pérez

et al. 2023

American J Hematol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

OAB-049: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)–related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)

Cited by 1 publication

References 0 publications

Association between dexamethasone exposure and visually significant cataracts in multiple myeloma

Association between dexamethasone exposure and visually significant cataracts in multiple myeloma

Contact Info

Product

Resources

About